Member of the Board since 2017 and Chair since July 2018.
Lars Rebien Sørensen was born in 1954 and is a Danish national. He received an MSc in Forestry from Copenhagen Royal Veterinary and Agricultural University in 1981 and a BSc in International Economics from Copenhagen Business School in 1983.
Lars Rebien Sørensen has more than 35 years of general management experience in the pharmaceutical industry. He joined Novozymes A/S (then Novo Nordisk A/S, Enzymes Division) in 1982. Over the years, he has held various global positions across the Middle East and the United States. In 1994, he was appointed as member of the corporate management team and assumed responsibility for Novozymes A/S Healthcare Business. In November 2000, he became President and CEO of Novo Nordisk A/S, a position he held until December 2016.
In 2007, Lars Rebien Sørensen was appointed as Adjunct Professor at the University of Copenhagen’s School of Life Sciences, and in 2018 he also became Adjunct Professor at the Center for Corporate Governance at CBS.
In addition to being Chair of the Board of Novo Holdings A/S, Lars Rebien Sørensen currently serves as Chair of the Board of the Novo Nordisk Foundation as well as Chair of the Advisory Board of Axcel Management A/S. He is furthermore a board member of Thermo Fischer Scientific Inc. based in the United States, of Essity AB based in Sweden, and of Jungbunzlauer Suisse AG based in Switzerland.